Search This Blog

Tuesday, June 25, 2019

EMA accepts Pacira’s application for Exparel for postsurgical pain

The European Medicines Agency (EMA) accepts for review Pacira BioSciences’ (NASDAQ:PCRX) marketing application seeking approval for EXPAREL (bupivacaine liposome injectable suspension) for the treatment of postsurgical pain.
The advisory group CHMP should issue an opinion sometime in H2 2020.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)